Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Pavia – page 18

587 clinical trials in Pavia, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pavia at a glance
587
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

587 trials in Pavia

Open in trial search

Study on Radiotherapy Alone or with Obinutuzumab for Patients with Early Stage Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Study of Pembrolizumab and Chemotherapy for Patients with Locally Advanced Sinonasal Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb

IgA nephropathy

Recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study on Lowering INR to Reduce Bleeding in Patients with Mechanical Aortic Valves Using Warfarin, Acenocoumarol, and Phenprocoumon

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Hamilton Health Sciences Corporation

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Asthma

Recruiting

Study on Tezepelumab for Children Aged 5 to 11 with Severe Asthma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study on the Safety and Effects of Radiprodil for Children with GRIN-related Disorder

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Radiprodil
  • Sponsor:Grin Therapeutics Inc.

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Pavia

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for cardiac conditions, including research on TTR amyloidosis and specialized therapies for pulmonary hypertension.

  • Heart Disease Prevention
  • Pulmonary Arterial Hypertension
  • Ventricular Tachycardia

Clinical trials evaluating new therapeutic approaches for cardiovascular complications and heart rhythm disorders.

02 Neurological Disorders

Studies investigating treatments for acute ischemic stroke and progressive neurological conditions, with particular focus on improving patient outcomes and functional recovery.

  • Stroke Treatment
  • Parkinson's Disease
  • Dravet Syndrome

Advanced research exploring innovative therapeutic approaches for various neurological conditions.

03 Autoimmune and Inflammatory Conditions

Research targeting chronic spontaneous urticaria, various forms of arthritis, and systemic autoimmune conditions affecting multiple organ systems.

  • Psoriatic Arthritis
  • Systemic Sclerosis
  • Immune System Disorders

Evaluation of novel therapies aimed at managing inflammatory responses and improving quality of life.

04 Respiratory Medicine

Comprehensive studies on chronic obstructive pulmonary disease and bronchiectasis, focusing on exacerbation prevention and symptom management.

  • COPD Treatment
  • Non-Cystic Fibrosis Bronchiectasis
  • Lung Fibrosis

Investigation of innovative therapeutic approaches for chronic respiratory conditions.

05 Hematology and Oncology

Advanced research in multiple myeloma and related blood disorders, including chronic myeloid leukemia and myelodysplastic syndromes.

  • Blood Cancers
  • Amyloidosis
  • Transfusion-Dependent Anemia

Development of targeted therapies for various hematological conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.